BREAKING—FDA has granted emergency use authorization for @Regeneron’s monoclonal antibody cocktail REGEN-COV2 (Casirivimab and imdevimab), the same drug given to Trump when he was infected with #COVID19. Only for mild/moderate cases—not hospitalized. 🧵 fda.gov/news-events/pr… 
2) There are a lot of rules and FDA stipulations for REGEN-COV2 cocktail use though— cannot be used if patient on oxygen (Trump was) or hospitalized. Children must be 12 or old and weigh 40 kg or more.
regeneron.com/sites/default/…
regeneron.com/sites/default/…
3) And it’s only for those mild/moderate with “high risk of progressing to severe #COVID19”—and thus need to be defined carefully what constitutes high risk of progressing:
4) unclear price yet. But monoclonal antibodies are expensive and slow to produce because they require biological reactor chambers (rather than pure chemistry combinations of chemicals).
5) that said, “Regeneron now expects to have REGEN-COV2 treatment doses ready for approximately 80,000 patients by the end of November, approximately 200,000 patients by the first week of Jan, and ~ 300,000 patients in total by the end of Jan 2021.” prnewswire.com/news-releases/…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
